Zevra Therapeutics
Quarterly Financials
| Values in thousands | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|
Revenue | $12,043 | $3,695 | $4,449 | $3,425 |
Gross Profit | 10,677 | 1,392 | 876 | 160 |
EBITDA | -16,526 | -29,296 | -16,183 | -14,395 |
EBIT | -18,174 | -30,913 | -17,745 | -15,957 |
Net Income | -35,739 | -33,225 | -19,925 | -16,622 |
Net Change In Cash | 12,043 | 3,695 | 4,449 | 3,425 |
Free Cash Flow | -16,250 | -18,141 | -19,109 | -16,165 |
Cash | 33,785 | 54,039 | 39,260 | 42,849 |
Basic Shares | 46,251 | 47,808 | 41,899 | 41,778 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $23,612 | $27,461 | $10,458 | $28,650 |
Gross Profit | 16,195 | 24,516 | 10,115 | 26,591 |
EBITDA | -76,400 | -48,598 | -25,526 | -7,888 |
EBIT | -82,789 | -49,604 | -26,470 | -8,145 |
Net Income | -105,511 | -46,049 | -41,543 | -8,555 |
Net Change In Cash | 23,612 | 27,461 | 10,458 | 28,650 |
Free Cash Flow | -69,665 | -33,830 | -18,810 | 10,337 |
Cash | 33,785 | 43,049 | 65,466 | 112,346 |
Basic Shares | 46,251 | 35,452 | 34,488 | 29,766 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-12-31 | -$0.69 |
2024-09-30 | -$0.69 |
2024-06-30 | -$0.48 |
2024-03-31 | -$0.40 |
